[Antithrombotic agents in unstable angina. Review of clinical trials].
Antithrombotic treatment of unstable angina is a highly controversial subject. The development of new antithrombotics (anti Gp IIb-IIIa, hirudin) has led to numerous therapeutic trials. Anti Gp IIb-IIIa are very promising in this indication, especially the Reopro chimeric antibody (Abciximab). Hirudin and its derivatives have demonstrated an early, but ephemeral clinical benefit. Low molecular weight heparins appear to be more effective than non-fractioned heparin and are easier and safer to use.
Centre Hospitalier Emile Roux, Eaubonne.
M
M
Habis
M C
MC
Morice
D000789:Angina, Unstable / Q000188:drug therapy*; D001241:Aspirin; D000077144:Clopidogrel; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D013988:Ticlopidine / Q000031:analogs & derivatives
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
Les antithrombotiques de l'angor instable. Bilan des essais cliniques.